Anticancer compounds and sphingolipid metabolism in the colon

In Vivo

Volumn 19, Issue 1, 2005, Pages 293-300

  Duan, Rui Dong ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Anticancer agents; Colon; Review; Sphingolipid metabolism

Indexed keywords

ACETYLSALICYLIC ACID; ANTINEOPLASTIC AGENT; BOSWELLIC ACID; CAMPTOTHECIN DERIVATIVE; CERAMIDE; CERAMIDE DERIVATIVE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DAUNORUBICIN; FENRETINIDE; GLUCOSIDASE; GLUCOSYLCERAMIDE; INDOMETACIN; LACTOSYLCERAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PALMITOYL COENZYME A; PHOSPHATIDYLCHOLINE; PIROXICAM; PROTEIN KINASE C; SAFINGOL; SERINE; SERINE PALMITOYLTRANSFERASE; SPHINGOLIPID; SPHINGOMYELIN; SPHINGOMYELIN PHOSPHODIESTERASE; SPHINGOSINE; SPHINGOSINE KINASE; SULINDAC; UNINDEXED DRUG; URSOLIC ACID;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL; CELL DIFFERENTIATION; COLON CANCER; COLON CARCINOGENESIS; DIET SUPPLEMENTATION; DIETARY INTAKE; DRUG MECHANISM; DRUG TARGETING; ENZYME INHIBITION; HUMAN; LIPID METABOLISM; MOLECULAR MECHANICS; NONHUMAN; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION;

EID: 16244365239     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (73)

1. Hannun YA and Bell RM: Functions of sphingolipids and sphingolipid breakdown products in cellular regulation. Science 243 500-507, 1989.
2. Pettus BJ, Chalfant CE and Hannun YA: Ceramide in apoptosis: an overview and current perspectives. Biochim Biophys Acta 1585: 114-125, 2002.
3. Hannun YA and Obeid LM: The Ceramide-centric universe of lipid-mediated cell regulation: stress encounters of the lipid kind. J Biol Chem 277: 25847-25850, 2002.
4. Cuvillier O: Sphingosine in apoptosis signaling. Biochim Biophys Acta 1585: 153-62, 2002.
5. Spiegel S and Milstien S: Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat Rev Mol Cell Biol 4: 397-407, 2003.
6. Brasitus TA, Dudeja PK and Dahiya R: Premalignant alterations in the lipid composition and fluidity of colonic brush border membranes of rats administered 1,2 dimethylhydrazine. J Clin Invest 77: 831-840, 1986.
7. Merchant TE, Diamantis PM, Lauwers G, Haida T, Kasimos JN, Guillem J, Glonek T and Minsky BD: Characterization of malignant colon tumors with 31P nuclear magnetic resonance phospholipid and phosphatic metabolite profiles. Cancer 76: 1715-1723, 1995.
8. Selzner M, Bielawska A, Morse MA, Rudiger HA, Sindram D, Hannun YA and Clavien PA: Induction of apoptotic cell death and prevention of tumor growth by ceramide analogues in metastatic human colon cancer. Cancer Res 61: 1233-1240, 2001.
9. Dillehay DL, Webb SK, Schmelz EM and Merrill AH: Dietary sphingomyelin inhibits 1,2-dimethylhydrazine-induced colon cancer in CF1 mice. J Nutr 124: 615-620, 1994.
10. Schmelz EM, Dillehay DL, Webb SK, Reiter A, Adams J and Merrill AH Jr: Sphingomyelin consumption suppresses aberrant colonic crypt foci and increases the proportion of adenomas versus adenocarcinomas in CF1 mice treated with 1,2-dimethylhydrazine: implications for dietary sphingolipids and colon carcinogenesis. Cancer Res 56: 4936-4941, 1996.
11. Schmelz EM, Bushnev AS, Dillehay DL, Liotta DC and Merrill AH Jr: Suppression of aberrant colonic crypt foci by synthetic sphingomyelins with saturated or unsaturated sphingoid base backbones. Nutr Cancer 28: 81-85, 1997.
12. Schmelz EM and Merrill AH Jr: Ceramides and ceramide metabolites in cell regulation: evidence for dietary sphingolipids as inhibitors of colon carcinogenesis. Nutrition 14: 717-719, 1998.
13. Schmelz E, Bushnev A, Dillehan DL, Sullards M, Liotta D and Merrill AH Jr: Ceramide-beta-D-glucuronide: synthesis, digestion, and suppression of early markers of colon carcinogenesis. Cancer Res 59 5768-5772, 1999.
14. Schmelz EM, Sullards MC, Dillehay DL and Merrill AH Jr: Colonic cell proliferation and aberrant crypt foci formation are inhibited by dairy glycosphingolipids in 1,2-dimethylhydrazine-treated CF1 mice. J Nutr 130: 522-527, 2000.
15. Nilsson Å: Metabolism of sphingomyelin in the intestinal tract of the rat. Biochim Biophys Acta 164: 575-584, 1968.
16. Nyberg L, Nilsson Å, Lundgren P and Duan RD: Localization and capacity of sphingomyelin digestion in the rat intestinal tract. J Nutr Biochem 8: 112-118, 1997.
17. Ahn EH and Schroeder JJ: Sphingoid bases and ceramide induce apoptosis in HT-29 and HCT-116 human colon cancer cells. Exp Biol Med (Maywood) 227: 345-353, 2002.
18. Nilsson Å and Duan RD: Alkaline sphingomyelinases and ceramidases of the gastrointestinal tract. Chem Phys Lipids 102: 97-105, 1999.
19. Duan RD, Bergman T, Xu N, Wu J, Cheng Y, Duan J, Nelander S, Palmberg C and Nilsson Å: Identification of human intestinal alkaline sphingomyelinase as a novel ecto-enzyme related to the nucleotide phosphodiesterase family. J Biol Chem 278: 38528-38536, 2003.
20. Duan RD, Nyberg L and Nilsson Å: Alkaline sphingomyelinase activity in rat gastrointestinal tract: distribution and characteristics. Biochim Biophys Acta 1259: 49-55, 1995.
21. Nilsson A, Hertervig E and Duan RD: Digestion and absorption of sphingolipids in food. In: Szuhaj BF and van Nieuwenhuyzen W (eds.), Nutrition and Biochemistry of Phospholipids. AOCS Press, Champaign, pp. 70-79, 2003.
22. Hertervig E, Nilsson A, Cheng Y and Duan RD: Purified intestinal alkaline sphingomyelinase inhibits proliferation without inducing apoptosis in HT-29 colon carcinoma cells. J Cancer Res Clin Oncol 129: 577-582, 2003
23. Hertervig E, Nilsson Å, Nyberg L and Duan RD: Alkaline sphingomyelinase activity is decreased in human colorectal carcinoma. Cancer 79: 448-453, 1996.
24. Hertervig E, Nilsson Å, Björk J, Hultkrantz R and Duan RD: Familial adenomatous polyposis is associated with a marked decrease in alkaline sphingomyelinase activity; a key factor to the unrestrained cell proliferation. Br J Cancer 81: 232-236, 1999.
25. Sjöqvist U, Hertervig E, Nilsson Å, Duan RD, Ost A, Tribukait B and Lofberg R: Chronic colitis is associated with a reduction of mucosal alkaline sphingomyelinase activity. Inflamm Bowel Dis 8: 258-263, 2002.
26. Wu J, Cheng Y, Nilsson Å and Duan RD: Identification of one exon deletion of intestinal alkaline sphingomyelinase in colon cancer HT-29 cells and a differentiation-related expression of the wild-type enzyme in Caco-2 cells. Carcinogenesis 25: 1327-1333, 2004.
27. Olsson M, Duan RD, Ohlsson L and Nilsson Å: Rat intestinal ceramidase: purification, properties, and physiological relevance. Am J Physiol Gastrointest Liver Physiol 287: G929-937, 2004.
28. Lundgren P, Nilsson Å and Duan RD: Distribution and properties of neutral ceramidase activity in rat intestinal tract. Dig Dis Sci 46: 765-772, 2001.
29. Duan RD, Cheng Y, Yang L, Ohlsson L and Nilsson Å: Evidence for specific ceramidase present in the intestinal contents of rats and humans. Lipids 36: 807-812, 2001.
30. Brady RO, Gal AE, Kanfer JN and Bradley RM: The metabolism of glucocerebrosides. 3. Purification and properties of a glucosyl- and galactosylceramide-cleaving enzyme from rat intestinal tissue. J Biol Chem 240: 3766-3770, 1965.
31. Leese HJ and Semenza G: On the identity between the small intestinal enzymes phlorizin hydrolase and glycosylceramidase. J Biol Chem 248: 8170-8173, 1973.
32. Kobayashi T and Suzuki K: A taurodeoxycholate-activated galactosylceramidase in the murine intestine. J Biol Chem 256: 1133-1137, 1981.
33. Kobayashi T and Suzuki K: The glycosylceramidase in the murine intestine. Purification and substrate specificity. J Biol Chem 256: 7768-7773, 1981.
34. Larson G, Falk P and Hoskins LC: Degradation of human intestinal glycosphingolipids by extracellular glycosidases from mucin-degrading bacteria of the human fecal flora. J Biol Chem 263: 10790-10798, 1988.
35. Falk P, Hoskins LC and Larson G: Enhancing effects of bile salts on the degradation of glycosphingolipids by glycosidases from bacteria of the human fecal flora. Biochim Biophys Acta 1084: 139-148, 1991.
36. Exon JH and South EH: Effects of sphingomyelin on aberrant colonic crypt foci development, colon crypt cell proliferation and immune function in an aging rat tumor model. Food Chem Toxicol 41: 471-476, 2003.
37. Lemonnier LA, Dillehay DL, Vespremi MJ, Abrams J, Brody E and Schmelz EM: Sphingomyelin in the suppression of colon tumors: prevention versus intervention. Arch Biochem Biophys 419: 129-138, 2003.
38. Symolon H, Schmelz EM, Dillehay DL and Merrill AH Jr: Dietary soy sphingolipids suppress tumorigenesis and gene expression in 1,2-dimethylhydrazine-treated CF1 mice and ApcMin/+ mice. J Nutr 134 1157-1161, 2004.
39. Modrak DE, Lew W, Goldenberg DM and Blumenthal R: Sphingomyelin potentiates chemotherapy of human cancer xenografts. Biochem Biophys Res Commun 268: 603-606, 2000.
40. Moschetta A, Portincasa P, van Erpecum KJ, Debellis L, Vanberge-Henegouwen GP and Palasciano G: Sphingomyelin protects against apoptosis and hyperproliferation induced by deoxycholate: potential implications for colon cancer. Dig Dis Sci 48: 1094-1101, 2003.
41. Motouri M, Matsuyama H, Yamamura J, Tanaka M, Aoe S, Iwanaga T and Kawakami H: Milk sphingomyelin accelerates enzymatic and morphological maturation of the intestine in artificially reared rats. J Pediatr Gastroenterol Nutr 36: 241-247, 2003.
42. Bose R, Verheij M, Haimovitz-Friedman A, Scotto K, Fuks Z and Kolesnick R: Ceramide synthase mediates daunorubicin-induced apoptosis: an alternative mechanism for generating death signals. Cell 82: 405-414, 1995.
43. Maurer BJ, Melton L, Billups C, Cabot MC and Reynolds CP: Synergistic cytotoxicity in solid tumor cell lines between N-(4-hydroxyphenyl)retinamide and modulators of ceramide metabolism. J Natl Cancer Inst 92: 1897-1909, 2000.
44. Chauvier D, Morjani H and Manfait M: Ceramide involvement in homocamptothecin- and camptothecin-induced cytotoxicity and apoptosis in colon HT29 cells. Int J Oncol 20: 855-863, 2002.
45. Huls G, Koornstra JJ and Kleibeuker JH: Non-steroidal anti-inflammatory drugs and molecular carcinogenesis of colorectal carcinomas. Lancet 362: 230-232, 2003.
46. Jayadev S, Linardic CM and Hannun YA: Identification of arachidonic acid as a mediator of sphingomyelin hydrolysis in response to tumor necrosis factor alpha. J Biol Chem 269: 5757-5763, 1994.
47. Liu JJ, Nilsson Å and Duan RD: In vitro effects of fat, fatty acids, and cholesterol on sphingomyelin hydrolysis induced by rat intestinal alkaline sphingomyelinase. Lipids 37: 469-474, 2002, 2002.
48. Allgayer H and Kruis W: Aminosalicylates: potential antineoplastic actions in colon cancer. Scand J Gastroenterol 37: 125-131, 2002.
49. Duan RD: Potential link between sphingomyelin metabolism and colonic tumorigenesis. In: Scheppach W and Scheurlen M (eds.), Exogenous Factors in Colonic Carcinogenesis. Kluwer Academic Publishers, Lancaster, UK., pp. 142-153, 2003.
50. Liu JJ, Nilsson Å, Oredsson S, Badmaev V, Zhao WZ and Duan RD: Boswellic acids trigger apoptosis via a pathway dependent on caspase-8 activation but independent on Fas/Fas ligand interaction in colon cancer HT-29 cells. Carcinogenesis 23: 2087-2093, 2002.
51. Andersson D, Liu JJ, Nilsson Å and Duan RD: Ursolic acid inhibits proliferation and stimulates apoptosis in HT29 cells following activation of alkaline sphingomyelinase. Anticancer Res 23: 3317-3322, 2003.
52. Earnest DL, Holubec H, Wali RK, Jolley CS, Bissonette M, Bhattacharyya AK, Roy H, Khare S and Brasitus TA: Chemoprevention of azoxymethane-induced colonic carcinogenesis by supplemental dietary ursodeoxycholic acid. Cancer Res 54: 5071-5074, 1994.
53. Khare S, Cerda S, Wali RK, von Lintig FC, Tretiakova M, Joseph L, Stoiber D, Cohen G, Nimmagadda K, Hart J, Sitrin MD, Boss GR and Bissonnette M: Ursodeoxycholic acid inhibits Ras mutations, wild-type Ras activation, and cyclooxygenase-2 expression in colon cancer. Cancer Res 63: 3517-3523, 2003.
54. Pardi DS, Loftus EV Jr, Kremers WK, Keach J and Lindor KD: Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 124: 889-893, 2003.
55. Cheng Y, Tauschel HT, Nilsson Å and Duan RD: Administration of ursodeoxycholic acid increases the activities of alkaline sphingomyelinase and caspase-3 in rat colon. Scand J Gastroenterol 34: 915-920, 1999.
56. Stennicke HR and Salvesen GS: Properties of the caspases. Biochim Biophys Acta 1387: 17-31, 1998.
57. Awad AB, Chen YC, Fink CS and Hennessey T: beta-Sitosterol inhibits HT-29 human colon cancer cell growth and alters membrane lipids. Anticancer Res 16: 2797-2804,1996.
58. von Holtz RL, Fink CS and Awad AB: beta-Sitosterol activates the sphingomyelin cycle and induces apoptosis in LNCaP human prostate cancer cells. Nutr Cancer 32: 8-12,1998.
59. Raicht R.F, Cohen BI, Fazzini EP, Sarwal AN and Takahashi M: Protective effect of plant sterols against chemically induced colon tumors in rats. Cancer Res 40: 403-405, 1980.
60. Normen AL, Brants HA, Voorrips LE, Andersson HA, van den Brandt PA and Goldbohm RA: Plant sterol intakes and colorectal cancer risk in the Netherlands Cohort Study on Diet and Cancer. Am J Clin Nutr 74: 141-148, 2001.
61. Jiang YH, Lupton JR, Chang WC, Jolly CA, Aukema HM and Chapkin RS: Dietary fat and fiber differentially alter intracellular second messengers during tumor development in rat colon. Carcinogenesis 17: 1227-1233,1996.
62. Pajari AM, Häkkänen P, Duan RD and Mutanen M: Role of red meat and arachidonic acid in protein kinase C activation in rat colonic musosa. Nutr Cancer 32: 86-94, 1998.
63. Cheng Y, Ohlsson L and Duan RD: Psyllium and fat in diets differentially affect the activities and expressions of colonic sphingomyelinases and caspase in mice. Br J Nutr 91: 715-723, 2004.
64. Yang L, Mutanen M, Cheng Y and Duan RD: Effects of fat, beef and fiber in diets on activities of sphingomyelinase, ceramidase and caspase-3 in rat colonic mucosa. Med Princ Pract 11: 150-156, 2002.
65. Yang L, Mutanen M, Cheng Y and Duan RD: Effects of red meat and fiber in high fat diet on activities of sphingomyelinase, ceramidase and caspase-3 in rat colonic mucosa. J Nutr Biochem 13: 499-504, 2002.
66. Lucci A, Giuliano AE, Han TY, Dinur T, Liu YY, Senchenkov A and Cabot MC: Ceramide toxicity and metabolism differ in wild-type and multidrug-resistant cancer cells. Int J Oncol 15: 535-540,1999.
67. Lavie Y, Cao H, Volner A, Lucci A, Han TY, Geffen V, Giuliano AE and Cabot MC: Agents that reverse multidrug resistance, tamoxifen, verapamil, and cyclosporin A, block glycosphingolipid metabolism by inhibiting ceramide glycosylation in human cancer cells. J Biol Chem 272: 1682-1687, 1997.
68. Gouaze V, Yu JY, Bleicher RJ, Han TY, Liu YY, Wang H, Gottesman MM, Bitterman A, Giuliano AE and Cabot MC: Overexpression of glucosylceramide synthase and P-glycoprotein in cancer cells selected for resistance to natural product chemotherapy. Mol Cancer Ther 3: 633-639, 2004.
69. Klappe K, Hinrichs JW, Kroesen BJ, Sietsma H and Kok JW: MRP1 and glucosylceramide are coordinately over expressed and enriched in rafts during multidrug resistance acquisition in colon cancer cells. Int J Cancer 110: 511-522, 2004.
70. Abe A, Radin NS, Shayman JA, Wotring LL, Zipkin RE, Sivakumar R, Ruggier JM, Carson KG and Ganem B: Structural and stereochemical studies of potent inhibitors of glucosylceramide synthase and tumor cell growth. J Lipid Res 36: 611-621, 1995.
71. Macchia M, Barontini S, Bertini S, Di Bussolo V, Fogli S, Giovannetti E, Grossi E, Minutolo F and Danesi R: Design, synthesis, and characterization of the antitumor activity of novel ceramide analogues. J Med Chem 44: 3994-4000, 2001.
72. Radin NS: Killing tumours by ceramide-induced apoptosis: a critique of available drugs. Biochem J 371: 243-256, 2003.
73. Radin NS: Poly-drug cancer therapy based on ceramide. Eksp Onkol 26: 3-10, 2004.